Sun Pharmaceutical Industries quarterly results

Q1 FY27 · Apr–Jun 2026

₹ crore	Q1 FY27	Q1 FY26	Change
Revenue	15,300	13,851	+10.5%
EBITDA	4,418	4,302	+2.7%
EBITDA margin	28.9%	31.1%	−2.2 pts
Profit before tax	4,099	3,173	+29.2%
Net profit	2,901	2,293	+26.5%
EPS	₹12.10	₹9.50	+27.4%

Every quarter

₹ crore except per share

Tap a line for its trend	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024	Q2 FY25Sep 2024	Q1 FY25Jun 2024	Q4 FY24Mar 2024	Q3 FY24Dec 2023	Q2 FY24Sep 2023	Earlier quartersAlpha Plus

Expenses
	15,300	14,612	15,521	14,478	13,851	12,959	13,675	13,291	12,653	11,983	12,381	12,192	Earlier quartersEvery year the company has filed comes with Alpha Plus.
	724	459	579	470	464	613	466	354	533	606	250	294
	16,024	15,070	16,099	14,948	14,316	13,572	14,141	13,645	13,185	12,589	12,631	12,486
	2,026	2,182	1,813	1,622	1,772	1,845	1,408	1,639	1,557	1,677	1,710	1,665
	1,020	753	922	1,088	1,048	1,037	1,239	875	997	983	796	1,007
	−82.6	−135	209	273	−4.8	−245	93.5	180	121	−279	231	115
	3,227	2,960	2,892	2,765	2,802	2,489	2,552	2,478	2,455	2,299	2,363	2,364
	99.7	85.9	78.4	99.9	74.8	49.1	51.5	69.2	61.5	73.6	34.7	49.3
	739	775	732	730	701	664	631	626	655	650	622	633
	4,692	4,896	4,735	4,204	3,933	4,117	4,374	4,181	3,915	4,268	3,804	3,862
	11,721	11,519	11,383	10,781	10,325	9,956	10,349	10,048	9,762	9,672	9,561	9,695
	4,418	3,954	4,948	4,527	4,302	3,716	4,009	3,939	3,608	3,035	3,477	3,179
	3,679	3,179	4,216	3,798	3,601	3,052	3,378	3,313	2,952	2,385	2,855	2,547
Profit
	4,303	3,551	4,717	4,168	3,991	3,616	3,793	3,598	3,424	2,917	3,070	2,791
	−204	0.0	−489	0.0	−818	−362	−316	0.0	0.0	−102	−69.8	0.0
	4,099	3,551	4,227	4,168	3,173	3,254	3,476	3,598	3,424	2,816	3,000	2,791
	1,188	828	826	1,031	870	1,094	559	567	552	149	432	390
	1,188	828	826	1,031	870	1,094	559	567	552	149	432	390
	−9.6	−14.1	−19.9	−12.1	−9.8	−6.7	−4.6	6.7	−10.7	−7.9	−7.5	−15.7
	2,901	2,710	3,381	3,125	2,293	2,154	2,913	3,037	2,861	2,659	2,561	2,385
	2,911	2,724	3,401	3,137	2,303	2,161	2,918	3,031	2,871	2,667	2,568	2,401
	1,509	1,503	781	1,415	127	335	118	418	41.4	281	425	219
	4,410	4,213	4,162	4,540	2,420	2,489	3,031	3,455	2,902	2,940	2,985	2,604
	2,895	2,714	3,369	3,118	2,279	2,150	2,903	3,040	2,836	2,655	2,524	2,376
	6.4	−4.4	12.4	7.0	14.2	4.1	9.6	−2.8	24.9	4.2	36.8	9.6
Per share
	₹12.10	₹11.30	₹14.00	₹13.00	₹9.50	₹9.00	₹12.10	₹12.70	₹11.80	₹11.10	₹10.50	₹9.90
	₹12.10	₹11.30	₹14.00	₹13.00	₹9.50	₹9.00	₹12.10	₹12.70	₹11.80	₹11.10	₹10.50	₹9.90
Other comprehensive income — detail
	1,509	1,503	781	1,415	127	335	—	—	—	—	—	—
	1,240	−73.7	338	323	−284	120	−190	−13.2	38.2	345	97.1	−27.6
	88.9	13.8	94.1	78.9	−73.9	28.8	—	—	—	—	—	—
	—	—	—	—	—	—	−47.5	−4.8	12.0	101	−1.8	−9.4
	392	1,559	536	1,119	351	267	231	427	20.5	36.6	337	221
	34.3	−31.4	−0.6	−53.0	12.8	22.9	—	—	—	—	—	—
	—	—	—	—	—	—	−29.5	0.4	5.3	−0.2	10.5	−16.8
	4,408	4,214	4,146	4,525	2,396	2,481	3,034	3,445	2,879	2,916	2,912	2,557
	2.1	−0.5	15.4	15.0	24.4	7.9	−2.8	10.2	23.0	23.8	73.3	47.0
Per share — as-filed variants
	₹12.10	₹11.30	₹14.00	₹13.00	₹9.50	₹9.00	₹12.10	₹12.70	₹11.80	₹11.10	₹10.50	₹9.90
	₹12.10	₹11.30	₹14.00	₹13.00	₹9.50	₹9.00	₹12.10	₹12.70	₹11.80	₹11.10	₹10.50	₹9.90
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	12,337	11,811	12,575	11,496	11,037	10,322	10,935	10,597	9,977	9,602	9,644	9,405
	80.6%	80.8%	81.0%	79.4%	79.7%	79.6%	80.0%	79.7%	78.9%	80.1%	77.9%	77.1%
Adjusted (ex-exceptional items) — derived
	4,303	3,551	4,717	4,168	3,991	3,616	3,793	3,598	3,424	2,917	3,070	2,791
	−204	0.0	−489	0.0	−818	−362	−316	0.0	0.0	−102	−69.8	0.0
	3,046	2,710	3,775	3,125	2,887	2,394	3,178	3,037	2,861	2,755	2,620	2,385
	₹12.70	₹11.30	₹15.63	₹13.00	₹11.96	₹10.00	₹13.20	₹12.70	₹11.80	₹11.50	₹10.75	₹9.90

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

SUNPHARMA₹1,757.50

Sun Pharmaceutical Industries Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersCIPLA DRREDDY LUPIN APOLLOHOSP MAXHEALTH DIVISLAB TORNTPHARM ZYDUSLIFEMcap ₹4.22L Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q2 FY24 30/09/2023	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026
Revenue from Operations	12,192.4	12,380.7	11,982.9	12,652.8	13,291.4	13,675.5	12,958.8	13,851.4	14,478.3	15,520.5	14,611.8	15,299.9
Other Income	293.6	250.2	605.9	532.6	354.0	465.6	612.9	464.5	469.9	578.8	458.5	723.6
Total Income	12,486.0	12,630.9	12,588.8	13,185.3	13,645.4	14,141.1	13,571.7	14,315.9	14,948.2	16,099.4	15,070.3	16,023.5
Expenses
+ Cost of Materials Consumed	1,665.5	1,709.7	1,676.7	1,557.0	1,638.7	1,408.3	1,845.1	1,771.6	1,621.5	1,813.5	2,182.4	2,026.3
+ Purchases of Stock-in-Trade	1,006.8	796.5	982.9	997.4	875.1	1,238.7	1,036.7	1,048.0	1,087.8	922.4	753.3	1,019.5
+ Changes in Inventories	114.8	230.8	-279.2	121.0	180.4	93.5	-244.6	-4.8	273.4	209.2	-134.7	-82.6
+ Employee Benefit Expense	2,364.4	2,363.3	2,299.3	2,454.6	2,477.7	2,552.3	2,488.5	2,801.7	2,764.8	2,892.0	2,960.4	3,227.2
+ Finance Costs	49.3	34.7	73.6	61.5	69.2	51.5	49.1	74.8	99.9	78.4	85.9	99.7
+ Depreciation & Amortisation	632.8	622.1	650.4	655.1	625.9	630.6	663.8	700.6	729.5	732.3	775.5	738.7
+ Other Expenses	3,861.6	3,803.6	4,268.0	3,915.1	4,180.5	4,373.6	4,117.0	3,933.3	4,203.7	4,735.0	4,896.1	4,691.8
Total Expenses	9,695.1	9,560.7	9,671.7	9,761.8	10,047.5	10,348.5	9,955.7	10,325.1	10,780.6	11,382.7	11,519.0	11,720.6
EBITDA	3,179.4	3,476.8	3,035.2	3,607.6	3,939.0	4,009.0	3,716.1	4,301.7	4,527.1	4,948.5	3,954.2	4,417.7
EBIT	2,546.6	2,854.7	2,384.8	2,952.5	3,313.1	3,378.5	3,052.3	3,601.1	3,797.6	4,216.2	3,178.7	3,679.0
Profit
PBT before Exceptional Items	2,790.9	3,070.2	2,917.2	3,423.5	3,597.9	3,792.6	3,616.0	3,990.8	4,167.6	4,716.6	3,551.3	4,302.9
+ Exceptional Items	0.0	-69.8	-101.6	0.0	0.0	-316.2	-361.7	-818.0	0.0	-489.5	0.0	-204.1
Pretax Income	2,790.9	3,000.4	2,815.5	3,423.5	3,597.9	3,476.4	3,254.4	3,172.8	4,167.6	4,227.2	3,551.3	4,098.8
+ Current Tax	390.1	432.3	148.9	552.3	567.2	558.9	1,093.7	870.2	1,030.5	826.1	827.6	1,188.0
Tax Expense	390.1	432.3	148.9	552.3	567.2	558.9	1,093.7	870.2	1,030.5	826.1	827.6	1,188.0
+ Share of Associates & JVs	-15.7	-7.5	-7.9	-10.7	6.7	-4.6	-6.7	-9.8	-12.1	-19.9	-14.1	-9.6
Net Income	2,385.1	2,560.5	2,658.7	2,860.5	3,037.3	2,913.0	2,153.9	2,292.9	3,125.0	3,381.2	2,709.7	2,901.2
+ Net Income — Continuing Ops	2,400.8	2,568.0	2,666.6	2,871.3	3,030.7	2,917.5	2,160.6	2,302.6	3,137.1	3,401.1	2,723.7	2,910.8
+ Other Comprehensive Income	219.3	424.9	281.3	41.4	417.8	117.9	335.3	127.4	1,415.4	780.5	1,503.4	1,509.2
Total Comprehensive Income	2,604.4	2,985.5	2,940.0	2,901.9	3,455.1	3,030.9	2,489.3	2,420.3	4,540.4	4,161.7	4,213.0	4,410.4
Net Income to Common	2,375.5	2,523.8	2,654.6	2,835.6	3,040.2	2,903.4	2,149.9	2,278.6	3,118.0	3,368.8	2,714.0	2,894.8
Minority Interest	9.6	36.8	4.2	24.9	-2.8	9.6	4.1	14.2	7.0	12.4	-4.4	6.4
Per Share
Basic EPS	9.90	10.50	11.10	11.80	12.70	12.10	9.00	9.50	13.00	14.00	11.30	12.10
Diluted EPS	9.90	10.50	11.10	11.80	12.70	12.10	9.00	9.50	13.00	14.00	11.30	12.10
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	—	335.3	127.4	1,415.4	780.5	1,503.4	1,509.2
+ Items NOT to be Reclassified to P&L	-27.6	97.1	345.4	38.2	-13.2	-189.8	119.8	-284.4	322.7	338.3	-73.7	1,240.4
+ Tax on Items NOT to be Reclassified	—	—	—	—	—	—	28.8	-73.9	78.9	94.1	13.8	88.9
+ Tax on Items NOT to be Reclassified — alt tag	-9.4	-1.8	100.8	12.0	-4.8	-47.5	—	—	—	—	—	—
+ Items to be Reclassified to P&L	220.7	336.6	36.6	20.5	426.6	230.8	267.2	350.7	1,118.6	535.7	1,559.4	391.9
+ Tax on Items to be Reclassified	—	—	—	—	—	—	22.9	12.8	-53.0	-0.6	-31.4	34.3
+ Tax on Items to be Reclassified — alt tag	-16.8	10.5	-0.2	5.3	0.4	-29.5	—	—	—	—	—	—
Comprehensive Income — Owners of Parent	2,557.3	2,912.1	2,916.2	2,878.9	3,444.9	3,033.7	2,481.3	2,395.9	4,525.4	4,146.3	4,213.5	4,408.3
Comprehensive Income — Non-controlling Interests	47.0	73.3	23.8	23.0	10.2	-2.8	7.9	24.4	15.0	15.4	-0.5	2.1
Per Share — as-filed variants
Basic EPS — Continuing Operations	9.90	10.50	11.10	11.80	12.70	12.10	9.00	9.50	13.00	14.00	11.30	12.10
Diluted EPS — Continuing Operations	9.90	10.50	11.10	11.80	12.70	12.10	9.00	9.50	13.00	14.00	11.30	12.10
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	9,405.3	9,643.8	9,602.5	9,977.3	10,597.2	10,934.9	10,321.7	11,036.6	11,495.6	12,575.4	11,810.7	12,336.7
Gross Margin %	77.14	77.89	80.13	78.85	79.73	79.96	79.65	79.68	79.40	81.02	80.83	80.63
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	2,790.9	3,070.2	2,917.2	3,423.5	3,597.9	3,792.6	3,616.0	3,990.8	4,167.6	4,716.6	3,551.3	4,302.9
− Exceptional Items (reconciliation)	0.0	-69.8	-101.6	0.0	0.0	-316.2	-361.7	-818.0	0.0	-489.5	0.0	-204.1
Net Income Adj (tax-effected)	2,385.1	2,620.3	2,755.0	2,860.5	3,037.3	3,178.3	2,394.1	2,886.5	3,125.0	3,775.0	2,709.7	3,046.2
EPS Adj	9.90	10.75	11.50	11.80	12.70	13.20	10.00	11.96	13.00	15.63	11.30	12.70
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	1.00	1.00	1.00	1.00	1.00	1.00	—	1.00	1.00	1.00	1.00	1.00
Paid Up Equity Capital	239.9	239.9	239.9	239.9	239.9	239.9	239.9	239.9	239.9	239.9	239.9	239.9

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Sun Pharma Q2 FY27 results date

Sun Pharmaceutical Industries (NSE: SUNPHARMA) will announce its Q2 FY27 results (July–September 2026) on Friday, 30 October 2026, according to the board-meeting notice it filed on 14 October 2026. Its latest results are for Q1 FY27 (April–June 2026). Consolidated net profit attributable to shareholders was ₹2,895 crore, up 27.0% from ₹2,279 crore in Q1 FY26 and up 6.7% from ₹2,714 crore in Q4 FY26. Revenue from operations was ₹15,300 crore, up 10.5% year on year and up 4.7% from the previous quarter.

Board-meeting notice filed: 14 October 2026
Q2 FY26 results (a year earlier): 5 November 2025
Q1 FY27 results (the latest): 31 July 2026

Latest results: Q1 FY27 (Apr–Jun 2026) · consolidated

Q2 FY27 results date: 30 October 2026Friday · notice filed 14 Oct
Q1 FY27 net profit: ₹2,895 Cr+27.0% vs Q1 FY26+6.7% vs Q4 FY26
Q1 FY27 revenue: ₹15,300 Cr+10.5% vs Q1 FY26+4.7% vs Q4 FY26
Q1 FY27 operating margin: 24.0%−2.0 pts vs Q1 FY26+2.3 pts vs Q4 FY26
Q2 FY26 net profit (a year earlier): ₹3,118 CrRevenue ₹14,478 Cr
Q1 FY27 EPS (basic): ₹12.10

Questions

When will Sun Pharma announce its Q2 FY27 results?

On 30 October 2026, the date of the board meeting called to approve them (notice filed with the exchanges on 14 October 2026). Last year it reported Q2 FY26 on 5 November 2025.

What were Sun Pharma's Q1 FY27 results?

Consolidated net profit attributable to shareholders was ₹2,895 crore, up 27.0% from ₹2,279 crore in Q1 FY26 and up 6.7% from ₹2,714 crore in Q4 FY26. Revenue from operations was ₹15,300 crore, up 10.5% year on year and up 4.7% from the previous quarter.

What was Sun Pharma's net profit in FY26?

Consolidated net profit attributable to shareholders was ₹11,479 crore in FY26 (April 2025–March 2026), up 5.0% from ₹10,929 crore in FY25. It was ₹9,576 crore in FY24 and ₹8,474 crore in FY23: up 35.5% over three years, 10.6% a year on average.

What will Sun Pharma's Q2 FY27 results be compared with?

With the same quarter a year earlier, Q2 FY26 (July–September 2025), when consolidated net profit attributable to shareholders was ₹3,118 crore and revenue from operations ₹14,478 crore. The latest quarter, Q1 FY27, had a net profit of ₹2,895 crore and revenue of ₹15,300 crore.

How has Sun Pharma's profit changed over the last four quarters?

Net profit attributable to shareholders by quarter: ₹3,118 crore in Q2 FY26, ₹3,369 crore in Q3 FY26, ₹2,714 crore in Q4 FY26 and ₹2,895 crore in Q1 FY27. That is ₹12,096 crore over the four quarters, up 16.6% from ₹10,372 crore in the four quarters before. Revenue from operations: ₹14,478 crore, ₹15,521 crore, ₹14,612 crore and ₹15,300 crore.

What was Sun Pharma's revenue in FY26?

Revenue from operations was ₹58,462 crore in FY26 (April 2025–March 2026), up 11.2% from ₹52,578 crore in FY25. It was ₹48,497 crore in FY24 and ₹43,886 crore in FY23: up 33.2% over three years, 10.0% a year on average.

Where do these Sun Pharma figures come from?

From Sun Pharmaceutical Industries' own consolidated results filings to NSE, in ₹ crore as filed; the date from its board-meeting notices.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.